http://edoc.rki.de/176904/43 2026-08-18T22:58:08Z 2026-08-18T22:58:08Z Hofmann, Heidelore Fingerle, Volker Huppertz, Hans-Iko Krause, Andreas Rauer, Sebastian Ruf, Bernhard Consensus Group Aberer, E. Bechter, K. Freitag, M. H. Großau, G. Gross, G. Müller, R. Müller, K. Berghoff, W. Pauschinger, M. Rieger, M. A. Schäfert, R. Thurau, S. Wallich, R. Wilking, H. http://edoc.rki.de/176904/13828 2026-08-18T13:27:24Z 2017-01-01T00:00:00Z

CutaneousLyme borreliosis: Guideline of the German Dermatology Society Hofmann, Heidelore; Fingerle, Volker; Huppertz, Hans-Iko; Krause, Andreas; Rauer, Sebastian; Ruf, Bernhard; Consensus Group; Aberer, E.; Bechter, K.; Freitag, M. H.; Großau, G.; Gross, G.; Müller, R.; Müller, K.; Berghoff, W.; Pauschinger, M.; Rieger, M. A.; Schäfert, R.; Thurau, S.; Wallich, R.; Wilking, H. This guideline of the German Dermatology Society primarily focuses on the diagnosis and treatment of cutaneous manifestations of Lyme borreliosis. It has received consensus from 22 German medical societies and 2 German patient organisations. It is the first part of an AWMF (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V.) interdisciplinary guideline: “Lyme Borreliosis – Diagnosis and Treatment, development stage S3”. The guideline is directed at physicians in private practices and clinics who treat Lyme borreliosis. Objectives of this guideline are recommendations for confirming a clinical diagnosis, recommendations for a stage-related laboratory diagnosis (serological detection of IgM and IgG Borrelia antibodies using the 2-tiered ELISA/immunoblot process, sensible use of molecular diagnostic and culture procedures) and recommendations for the treatment of the localised, early-stage infection (erythema migrans, erythema chronicum migrans, and borrelial lymphocytoma), the disseminated early-stage infection (multiple erythemata migrantia, flu-like symptoms) and treatment of the late-stage infection (acrodermatitis chronica atrophicans with and without neurological manifestations). In addition, an information sheet for patients containing recommendations for the prevention of Lyme borreliosis is attached to the guideline.

2017-01-01T00:00:00Z Kinross, Pete Petersen, Andreas Skov, Robert van Hauwermeiren, Evelyn Pantosti, Annalisa Laurent, Frédéric Voss, Andreas Kluytmans, Jan Struelens, Marc J. Heuer, Ole Monnet, Dominique L. the European human LA-MRSA study group Denis, Olivier Budimir, Ana Pieridou, Despo Žemličková, Helena Lindholm, Laura Layer, Franziska Spiliopoulou, Iris Petinaki, Efthymia Tóth, Ákos Haraldsson, Gunnstein Brennan, Gráinne I. Monaco, Monica Werner, Nicole Balode, Arta Olga Miciuleviciene, Jolanta Mossong, Joël Perrin, Monique Borg, Michael A. Larssen, Kjersti Wik Elstrøm, Petter Empel, Joanna Caniça, Manuela Manageiro, Vera Codita, Irina Nikš, Milan Dermota, Urška Pérez Vázquez, María Dolores Vindel, Ana Hæggman, Sara Mäkitalo, Barbro Kearns, Angela M. Pichon, Bruno http://edoc.rki.de/176904/13827 2026-08-18T12:57:27Z 2017-11-02T00:00:00Z

Livestock-associated meticillin-resistant Staphylococcus aureus (MRSA) among human MRSA isolates, European Union/European Economic Area countries, 2013 Kinross, Pete; Petersen, Andreas; Skov, Robert; van Hauwermeiren, Evelyn; Pantosti, Annalisa; Laurent, Frédéric; Voss, Andreas; Kluytmans, Jan; Struelens, Marc J.; Heuer, Ole; Monnet, Dominique L.; the European human LA-MRSA study group; Denis, Olivier; Budimir, Ana; Pieridou, Despo; Žemličková, Helena; Lindholm, Laura; Layer, Franziska; Spiliopoulou, Iris; Petinaki, Efthymia; Tóth, Ákos; Haraldsson, Gunnstein; Brennan, Gráinne I.; Monaco, Monica; Werner, Nicole; Balode, Arta Olga; Miciuleviciene, Jolanta; Mossong, Joël; Perrin, Monique; Borg, Michael A.; Larssen, Kjersti Wik; Elstrøm, Petter; Empel, Joanna; Caniça, Manuela; Manageiro, Vera; Codita, Irina; Nikš, Milan; Dermota, Urška; Pérez Vázquez, María Dolores; Vindel, Ana; Hæggman, Sara; Mäkitalo, Barbro; Kearns, Angela M.; Pichon, Bruno Currently, surveillance of livestock-associated meticillin-resistant Staphylococcus aureus (LA-MRSA) in humans in Europe is not systematic but mainly event-based. In September 2014, the European Centre for Disease Prevention and Control (ECDC) initiated a questionnaire to collect data on the number of LA-MRSA from human samples (one isolate per patient) from national/regional reference laboratories in European Union/European Economic Area (EU/EEA) countries in 2013. Identification of LA-MRSA as clonal complex (CC) 398 by multilocus sequence typing (MLST) was preferred, although surrogate methods such as spa-typing were also accepted. The questionnaire was returned by 28 laboratories in 27 EU/EEA countries. Overall, LA-MRSA represented 3.9% of 13,756 typed MRSA human isolates, but it represented ≥ 10% in five countries (Belgium, Denmark, Spain, the Netherlands and Slovenia). Seven of the reference laboratories did not type MRSA isolates in 2013. To monitor the dispersion of LA-MRSA and facilitate targeted control measures, we advocate periodic systematic surveys or integrated multi-sectorial surveillance.

2017-11-02T00:00:00Z Koch, Judith Harder, Thomas von Kries, Rüdiger Wichmann, Ole http://edoc.rki.de/176904/13826 2026-08-18T12:57:26Z 2017-01-01T00:00:00Z

Risk of Intussusception After Rotavirus Vaccination Koch, Judith; Harder, Thomas; von Kries, Rüdiger; Wichmann, Ole Background: In 2013, the German Standing Committee on Vaccination (Ständige Impfkommission, STIKO) recommended rotavirus (RV) vaccination for all infants while stating that this mildly increased the risk of intussusception, a potentially life-threatening event. Since this recommendation was issued, multiple observational studies on this topic designed as self-controlled case series (SCCS) have been published. The SCCS design is particularly suitable for the study of rare adverse effects of medications. Methods: We systematically searched the literature for SCCS studies on the risk of intussusception after RV vaccination. Relative risks (RR) corresponding to different doses of vaccine were summarized in a meta-analysis, and attributable risks (AR) were calculated. Results: Of the 16 initially identified studies, 10 with a predominantly low risk of bias were considered in the analysis. The RR for intussusception was 5.71 (95% confidence interval [4.50; 7.25]) 1–7 days after the first dose, 1.69 [1.33; 2.14] after the second, and 1.14 [0.75; 1.74] after the third. The AR for children of the age at which RV vaccination is recommended was 1.7 [1.1; 2.7] additional intussusceptions per 100 000 vaccinated children after the first dose and 0.25 [0.16; 0.40] after the second. If >3-month-old infants are vaccinated, the AR is higher: 5.6 [4.3; 7.2] per 100 000 after the first dose and 0.81 [0.63; 1.06] per 100 000 after the second. Conclusion: RV vaccination is associated with a markedly elevated RR and a mildly elevated AR for intussusception 1–7 days after the first dose. Physicians should begin the series of vaccinations at age 6–12 weeks, as recommended by the STIKO, because the risk of intussusception is higher afterward. Current health insurance company claim data indicate that 11.2% of infants are still receiving the first dose of the vaccine at ages above 3 months. The parents of vaccinated children should be informed about the possible signs of intussusception (colicky pain, bilious vomiting, and red “currant jelly” stool).

2017-01-01T00:00:00Z Kader Konde, Mandy Baker, Darren P. Traore, Fode Amara Sow, Mamadou Saliou Camara, Alioune Barry, Alpha Amadou Barry, Abdoulaye Coné, Moussa Kaba, Ibrahima Richard, Amento Ablam Beavogui, Abdoul Habib Günther, Stephan European Mobile Laboratory Consrotium Pintilie, Melanie Fish, Eleanor N. Duraffour, Sophie Bore, Joseph Akoi Raymond Koundouno, Fara Hinzmann, Julia Mertens, Marc Vitoriano, Inês Logue, Christopher H. Boettcher, Jan Peter Pallash, Elisa Sachse, Andreas Bah, Amadou Cabeza-Cabrerizo, Mar Mitzsche, Katja Kuisma, Eeva Michel, Janine Holm, Janine Zekeng, Elsa G. Garcia-Dorival, Isabel http://edoc.rki.de/176904/13825 2026-08-18T12:27:27Z 2017-02-22T00:00:00Z

Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial Kader Konde, Mandy; Baker, Darren P.; Traore, Fode Amara; Sow, Mamadou Saliou; Camara, Alioune; Barry, Alpha Amadou; Barry, Abdoulaye; Coné, Moussa; Kaba, Ibrahima; Richard, Amento Ablam; Beavogui, Abdoul Habib; Günther, Stephan; European Mobile Laboratory Consrotium; Pintilie, Melanie; Fish, Eleanor N.; Duraffour, Sophie; Bore, Joseph Akoi; Raymond Koundouno, Fara; Hinzmann, Julia; Mertens, Marc; Vitoriano, Inês; Logue, Christopher H.; Boettcher, Jan Peter; Pallash, Elisa; Sachse, Andreas; Bah, Amadou; Cabeza-Cabrerizo, Mar; Mitzsche, Katja; Kuisma, Eeva; Michel, Janine; Holm, Janine; Zekeng, Elsa G.; Garcia-Dorival, Isabel To date there are no approved antiviral drugs for the treatment of Ebola virus disease (EVD). Based on our in vitro evidence of antiviral activity of interferon (IFN)-ß activity against Ebola virus, we conducted a single arm clinical study in Guinea to evaluate the safety and therapeutic efficacy of IFN β-1a treatment for EVD. Nine individuals infected with Ebola virus were treated with IFN β-1a and compared retrospectively with a matched cohort of 21 infected patients receiving standardized supportive care only during the same time period at the same treatment unit. Cognizant of the limitations of having treated only 9 individuals with EVD, the data collected are cautiously considered. When compared to supportive care only, IFN β-1a treatment seemed to facilitate viral clearance from the blood and appeared associated with earlier resolution of disease symptoms. Survival, calculated from the date of consent for those in the trial and date of admission from those in the control cohort, to the date of death, was 19% for those receiving supportive care only, compared to 67% for those receiving supportive care plus IFN β-1a. Given the differences in baseline blood viremia between the control cohort and the IFN-treated cohort, an additional 17 controls were included for a subset analysis, from other treatment units in Guinea, matched with the IFN-treated patients based on age and baseline blood viremia. Subset analyses using this expanded control cohort suggests that patients without IFN β-1a treatment were ~ 1.5–1.9 fold more likely to die than those treated. Viewed altogether the results suggest a rationale for further clinical evaluation of IFN β-1a.

2017-02-22T00:00:00Z